Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Wuxi Biologics (2269 HK): Expanded Offering and Capacity Drive 1H25 Result; Accelerated Growth Ahead

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-apptec" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (2269 HK)</a> announced 2025 revenue growth of 17%, ahead of guidance of 14–16%. Gross margin improved to multi-year high of 46.0%. Net profit rose 45% YoY.</li>
<li>Wuxi Biologics added a record of 209 new integrated projects in 2025. Total backlog reached $23.7B (up 28% YoY) as of December 31, 2025, including $11.5B service backlog.</li>
<li>Wuxi Biologics guided for 2026 revenue growth of 13–17%. Solid 2H25 manufacturing margins are expected to expand further over time as commercial programs scale and utilization continues to improve.</li>
</ul>



Wuxi Biologics (2269 HK) announced 2025 revenue growth of 17%, ahead of guidance of 14–16%. Gross margin improved to multi-year high of 46.0%. Net profit rose 45% YoY.
Wuxi Biologics added a record of 209 new integrated projects in 2025. Total backlog reached $23.7B (up 28% YoY) as of December 31, 2025, including $11.5B service backlog.
Wuxi Biologics guided for 2026 revenue growth of 13–17%. Solid 2H25 manufacturing margins are expected to expand further over time as commercial programs scale and utilization continues to improve.


Wuxi Biologics (2269 HK): 2025 Revenue Beat Guidance; Poised for Accelerated Growth Ahead